

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/851,138	05/09/2001	Geert Maertens	2752-43	4881
23117	7590 01/11/2005		EXAM	INER
NIXON & VANDERHYE, PC 1100 N GLEBE ROAD			LI, BA	70 Ó
8TH FLOOR		ART UNIT	PAPER NUMBER	
ARLINGTON	, VA 22201-4714		1648	

DATE MAILED: 01/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Anglicantic				
•	Application No.	Applicant(s)				
Office Action Summary	09/851,138	MAERTENS ET AL.				
Office Action Summary	Examiner	Art Unit				
Th. 1111 110 DATE (1)	Bao Qun Li	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, and If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by so any reply received by the Office later than three months after the meanned patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, however, may a repl a reply within the statutory minimum of thirty (seriod will apply and will expire SIX (6) MONTH tatute, cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 2	8 October 2004.					
· <u> </u>						
· <u> </u>	,_					
closed in accordance with the practice und	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>63-70</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) 63, 65 in condition for allowance if claim 64 and its dependent claims are canceled or amended						
allowed.						
6)						
7) Claim(s) is/are objected to.	<u> </u>					
	Claim(s) are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
dee the attached detailed Office action for a list of the certified copies flot received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 10/28/2004. 5) Notice of Informal Patent Application (PTO-152) 6) Other:						

Art Unit: 1648

DETAILED ACTION

Response to Amendment

This is a response to the amendment, paper No. 26, filed 10/28/04. Claims 63, 64, 65,69 have been amended. Claims 1-62 have been canceled. Claims 62-70 are pending before the examiner.

Please note any ground of rejection(s) that has not been repeated is removed. Text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

Drawings

1. The drawings filed on 05/29/2003 has been accepted by the office.

Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 3. Claims 64, 66, 67, 68, 69 and 70 are still rejected under 35 U.S.C. 112, second paragraph on the same ground as stated in the previous Office Action as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 4. Applicants' traverse the rejection and argue the rejection is not completely understood by the applicants, as it is believed that only one HCV polyprotein, which is the product of translation of a single large open reading frame of the HCV genome, exists. Moreover, applicants submit that a definition of "HCV polyprotein" can be found, for example, on page 9, lines 7-12 of the specification. Further the claims have been amended to indicate the particular part of the HCV polyprotein, which is the subject matter of the claims.
- 5. Applicant's argument and the amendment filed 10/28/04 have been considered fully, but they are not persuasive. Because HCV is a virus is recognized as positive RNA quasispecies virus that mutates rapidly and automatically in adapting to the environments, thus it has a high

Application/Control Number: 09/851,138

Art Unit: 1648

genome divergence. A single isolated HCV strains even can generate more than a hundred clones in the most genetically heterogeneous region. Therefore, it can translate into more than one kind of HCV polypeptides that have different structural characteristics.

- 6. Moreover, it is unclear that claim 64 is drafted to be open or closed claim language, what exactly the claimed polynucleotides are intended to encompass. What the claimed polynucleic acid structured is? It is a sequence encoding an entire HCV polyprotein or a portion of the HCV polyprotein?
- 7. The specification regarding to the definition of HCV polyprotein on lines 7-12 on page 9 has been reviewed. The specification has been defined the HCV polyprotein as the HCV polyprotein of HCV-J isolate (Kato et al. 1990). However, this limitation cannot read into the claim, and the claim as drafted does not limit the claimed HCV polypeptide on the HCV polyprotein disclosed by Kato alone. Therefore, the structural characteristic of claim polynucleic acid sequence is unclear since there is no indication from where the counting of the amino acid residue of claimed HCV polyprotein starts. The rejection is still maintained. This affects the dependent claim 66, 67, 68, 69 and 70.

Conclusion

8. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 6:30 am to 3:30 pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao Qun Li

1/05/2004

SUPERVISORY PATENT EXAMINED TECHNOLOGY CENTER 1600